



Docket No.: 220051US0

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

165188

OBLON
SPIVAK
McCLELLAND
MAIER
&
NEUSTADT
P.C.

ATTORNEYS AT LAW

RECEIVED

JUL - 7 2003
TECH CENTER 1600/2900

RE: Application Serial No.: 10/082,082

Applicants: Munetetsu TEI

Filing Date: February 26, 2002

For: ANTITUMOR AND ANTIVIRAL MEDICATIONS
AND METHOD FOR PRODUCING THE SAME

Group Art Unit: 1651

Examiner: Vera Afremova

SIR:

Attached hereto for filing are the following papers:

Response to Requirement for Restriction; Request for Extension of Time (two month)

Our check in the amount of \$205.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Rohitha M. Jayasuriya
Registration No. 50,385

Application No. 10/082,082
Reply to Office Action of April 4, 2003



DOCKET NO: 220051US0

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

MUNETETSU TEI : EXAMINER: AFREMOVA, VERA

SERIAL NO: 10/082,082 :

FILED: FEBRUARY 26, 2002 : GROUP ART UNIT: 1651

FOR: ANTITUMOR AND ANTIVIRAL
MEDICATIONS AND METHOD FOR
PRODUCING THE SAME

RECEIVED

JUL - 7 2003

TECH CENTER 1600/2900

RESPONSE TO REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Official Action of April 4, 2003, Applicants elect, with traverse,
Group I, Claims 1-36, drawn to an antitumor and antiviral medication with activated
lymphocytes.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 1-36, drawn to an antitumor and antiviral medication with
activated lymphocytes;

Group II: Claims 37 and 38, drawn to an antitumor medication consisting of
reserpine derived from *Rauwolfia serpentina*;

Group III: Claims 39-50, drawn to a method for producing antitumor and antiviral
medication with activated heat treated lymphocytes;

Group IV: Claims 51 and 52, drawn to a method for producing antitumor and
antiviral medication with activated lymphocytes treated with galenical
extract of crude drugs;